Company profile for Ractigen Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Ractigen Therapeutics is an early-stage pharmaceutical company committed to bringing to market first-in-class therapies designed to selectively restore the expression of therapeutic genes silenced in diseased cells. Its core technology is based on a paradigm-shifting discovery made at the University of California San Francisco (UCSF) known as RNA activation (RNAa). Founded in 2016 by the pioneers in the field, Ractigen is deve...
Ractigen Therapeutics is an early-stage pharmaceutical company committed to bringing to market first-in-class therapies designed to selectively restore the expression of therapeutic genes silenced in diseased cells. Its core technology is based on a paradigm-shifting discovery made at the University of California San Francisco (UCSF) known as RNA activation (RNAa). Founded in 2016 by the pioneers in the field, Ractigen is developing a rich pipeline of candidate medicines for patients with unmet need.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
China
Address
Address
Bldg.18, Rudong Life & Health Industry Park, 888 Zhujiang Rd, Rudong, Nantong,...
Telephone
Telephone
(+86) 513-81996959
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.prnewswire.com/news-releases/ractigen-therapeutics-doses-first-patient-in-iit-study-of-rag-18-a-potential-game-changing-sarna-therapeutic-for-duchenne-muscular-dystrophy-302640199.html

PR NEWSWIRE BIO
12 Dec 2025

https://www.prnewswire.com/news-releases/ractigens-rag-17-als-data-shines-at-aan-2025-earns-top-award-phase-i-advances-302424420.html

PR NEWSWIRE
09 Apr 2025

https://www.prnewswire.com/news-releases/ractigens-rag-01-shows-promising-early-complete-responses-in-phase-i-nmibc-trial-data-presented-at-eau-2025-302409218.html

PR NEWSWIRE
24 Mar 2025

https://www.prnewswire.com/news-releases/ractigen-therapeutics-founder-dr-long-cheng-li-awarded-2024-life-science-ice-breaking-award-302340610.html

PR NEWSWIRE
31 Dec 2024

https://www.prnewswire.com/news-releases/ractigen-therapeutics-announces-first-patient-dosed-in-phase-i-clinical-trial-for-rag-17-in-sod1-als-302338866.html

PR NEWSWIRE
24 Dec 2024

https://www.prnewswire.com/news-releases/ractigen-therapeutics-announces-fda-orphan-drug-designation-for-rag-21-for-the-treatment-of-als-302309985.html

PR NEWSWIRE
19 Nov 2024

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty